Table 1.

Demographic data: community- versus hospital-acquired AKI

VariableCA-AKI (n=686)HA-AKI (n=334)P Value
Mean age±SD (yr)74.4±15.476.8±130.01
Men, % (n)50.1 (342)48.2 (161)0.56
Preexisting CKD, % (n)33.2 (228)28.4 (95)0.12
Mean baseline creatinine (preadmission)±SD (μmol/L)a112±50.8107.6±33.50.68
Medical admission, % (n)86.2 (591)85.3 (285)0.72
Surgical admission, % (n)13.8 (95)14.7 (49)
ICU admission, % (n)4.7 (32)9.9 (33)0.002
Median length of hospital stay (IQR) (d)7 (3–16)15 (7–26)<0.001
AKI severity, % (n)
 Stage 142.4 (291)51.8 (173)0.01
 Stage 230.6 (210)27.5 (92)0.34
 Stage 327 (185)20.7 (69)0.03
Comorbid conditions, % (n)
 Congestive heart failure15.4 (103)19.8 (65)0.72
 Lung disease15.9 (107)21.3 (70)0.34
 Liver disease3.4 (23)4.0 (13)0.66
 Ischemic heart disease20.4 (137)26.5 (87)0.28
 Peripheral vascular disease3.4 (23)4.6 (15)0.37
 Cancer (within 5 yr)14.5 (97)12.2 (40)0.34
 Hypertension31.8 (213)31.4 (103)0.95
 Dementia8.2 (55)5.2 (17)0.13
 Diabetes24.5 (165)24 (79)0.89
 Cerebrovascular disease10.7 (72)14 (46)0.95
 Connective tissue disease3.1 (21)6.1 (20)0.03
  • Continuous, normally distributed data analyzed using t test. Non-normally distributed variables analyzed using Mann–Whitney U test. Analysis of spread of categorical variables calculated using Pearson chi-squared test or Fisher exact test where appropriate. Sixteen patients from CA-AKI group and 8 patients from HA-AKI group had no comorbidity data available. CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; ICU, intensive care unit; IQR, interquartile range.

  • a Baseline creatinine assessed as detailed in text. Forty-nine patients had no baseline creatinine available (41 in CA-AKI group and 8 in HA-AKI group).